Technology ID
TAB-3466
Methods of Synthesis of the Ketamine Analogs (2R, 6R)-kydroxynorketamine and (2S, 6S)-hydroxynorketamine for the Treatment of Pain and other Anxiety-related Disorders
Bookmark
[history] History Saved
E-Numbers
E-116-2016-0
Lead Inventor
Thomas, Craig (NCATS)
Co-Inventors
Zanos, Panos (University of Maryland, School of Medicine)
Gould, Todd (University of Maryland)
Morris, Patrick (NCATS)
Moaddel, Ruin (NIA)
Zarate, Carlos (NIMH)
Applications
Therapeutics
Therapeutic Areas
Psychiatry/Mental Health
Neurology
Lead IC
NCATS
ICs
NIMH
NIA
NCATS
This technology includes a method for synthesizing the ketamine analogs (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine that may be useful for the treatment of pain, depression, anxiety, and related disorders. The drug ketamine was first used as an anesthetic but was found to be an effective treatment in a range of conditions, including paint, treatment-resistant bipolar depression, and other anxiety-related disorders. However, the routine use of ketamine is hindered by unwanted side effects, including the potential for abuse. Ketamine analogs have the potential advantage of retaining the efficacy of ketamine while limiting unwanted side effects.
Commercial Applications
Further clinical work with these ketamine analogs could establish these as effective treatments for pain, depression, anxiety, and related disorders.
Competitive Advantages
Ketamine analogs including (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine have the potential advantage of retaining the efficacy of ketamine while limiting unwanted side effects.
Licensing Contact: